Meeting
2017 Gastrointestinal Cancers Symposium
Effect of polymorphisms of genes encoding regulatory proteins in the coagulation cascade on outcome for mCRC patients treated with FOLFIRI and bevacizumab: Data from FIRE-3 trial.
Authors
Martin D. Berger
Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA
Martin D. Berger , Sebastian Stintzing , Dongyun Yang , Mitsukuni Suenaga , Yuji Miyamoto , Shivani Soni , Roel Gopez Jr., Diana L. Hanna , Wu Zhang , Volker Heinemann , Heinz-Josef Lenz , Shu Cao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 601)
DOI
10.1200/JCO.2017.35.4_suppl.601
Abstract #
601
Poster Bd #
D19
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
MKNK1 SNP rs8602 to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
First Author: Martin D. Berger
Poster
2016 ASCO Annual Meeting
Polymorphisms of genes encoding for vitamin D binding protein and Wnt5a to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial.
First Author: Martin D. Berger
Poster
2020 Gastrointestinal Cancers Symposium
Polymorphisms of genes encoding for regulatory proteins in the coagulation cascade to predict outcome for stage II and III colon cancer.
First Author: Martin D. Berger
Poster
2018 Gastrointestinal Cancers Symposium
Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes to predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab in TRIBE trial.
First Author: Mitsukuni Suenaga